Varda raises $251M at a $1.6B valuation for orbital drug manufacturing

Varda Space Industries builds uncrewed capsules that process pharmaceutical samples in orbit and bring them back to drug developers on Earth. The company announced a $251 million Series D led by Lux Capital and Natural Capital; Reuters reported that the financing values Varda at $1.6 billion.

The work starts well before launch. Varda screens small molecules or biologics in terrestrial and hypergravity labs, prepares promising samples and loads them into a free-flying W-Series vehicle. In orbit, automated equipment heats, mixes and cools the material; a capsule then separates, reenters and lands by parachute so the sample can be recovered and analyzed.

The scientific bet is that removing gravity changes crystallization. Varda says microgravity suppresses convection, buoyancy and sedimentation, which can produce more uniform particles or crystal forms that are difficult to make on Earth. Those properties could improve formulation or drug delivery, but they still have to survive post-flight testing and, eventually, clinical development.

That makes Varda a pharmaceutical-development service wrapped inside a spaceflight company. The same capsules also offer government researchers hypersonic reentry conditions, a nearer-term market that outweighs the drug work in Varda’s disclosed 2027 mix: Chief Executive Will Bruey told Reuters that government programs account for about 70% of next year’s payload customer base, with commercial pharmaceutical missions making up the balance.

Varda has deployed six W-Series missions since 2023, according to Reuters. All six vehicles reentered, although the fourth capsule wasn’t recovered, Fierce Pharma reported. Each round trip matters because pharmaceutical customers need more than a one-off experiment: Varda’s model depends on recovering samples, measuring what changed and flying another iteration.

Varda says the round will fund more frequent flights and deeper pharmaceutical partnerships, lifting its total capital raised to $598 million. The capital is arriving before the company’s central pharmaceutical ambition has been reached: Bruey told Reuters that its biggest milestone would be putting a microgravity-enabled formulation into a human in the clinic around the turn of the decade.